The PRRT (Peptide Receptor Radionuclide Therapy) is a promising modality treatment for patients with inoperable or metastatic neuroendocrine tumors (NETs). Progression‐free survival (PFS) and overall survival (OS) of these patients are favorably comparable with standard therapies. The protagonist in this type of therapy is a somatostatin‐modified peptide fragment ([Tyr3] octreotide), equipped with a specific chelating system (DOTA) capable of creating a stable bond with β‐emitting radionuclides, such as yttrium‐90 and lutetium‐177. In this review, covering twenty five years of literature, we describe the characteristics and performances of the two most used therapeutic radiopharmaceuticals for the NETs radio‐treatment: [90Y]Y‐DOTATOC and [177Lu]Lu‐ DOTATOC taking this opportunity to retrace the most significant results that have determined their success, promoting them from preclinical studies to application in humans.
90 Y/177 Lu‐dotatoc From Preclinical Studies to Application in Humans
Uccelli L.Primo
;Boschi A.Secondo
;Cittanti C.
;Martini P.
;Panareo S.;Urso L.;Caracciolo M.;Carnevale A.;Giganti M.;Bartolomei M.Ultimo
2021
Abstract
The PRRT (Peptide Receptor Radionuclide Therapy) is a promising modality treatment for patients with inoperable or metastatic neuroendocrine tumors (NETs). Progression‐free survival (PFS) and overall survival (OS) of these patients are favorably comparable with standard therapies. The protagonist in this type of therapy is a somatostatin‐modified peptide fragment ([Tyr3] octreotide), equipped with a specific chelating system (DOTA) capable of creating a stable bond with β‐emitting radionuclides, such as yttrium‐90 and lutetium‐177. In this review, covering twenty five years of literature, we describe the characteristics and performances of the two most used therapeutic radiopharmaceuticals for the NETs radio‐treatment: [90Y]Y‐DOTATOC and [177Lu]Lu‐ DOTATOC taking this opportunity to retrace the most significant results that have determined their success, promoting them from preclinical studies to application in humans.File | Dimensione | Formato | |
---|---|---|---|
pharmaceutics-13-01463-v2.pdf
accesso aperto
Tipologia:
Full text (versione editoriale)
Licenza:
Creative commons
Dimensione
1.08 MB
Formato
Adobe PDF
|
1.08 MB | Adobe PDF | Visualizza/Apri |
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.